ClinicalTrials.gg
CompletedNCT00566722Updated Apr 12, 2011Results posted

Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

A Phase 3 interventional study of adalimumab in Psoriasis, sponsored by Abbott. Completed at 25 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-12.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
152
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
22nd of 48
152 · median 148
Started
2008
with 1 other
Phase 3
26 of 48
1 open now
Registered
5th of 48
by date
Lead sponsor
11 of 48
Abbott

Among the 48 studies testing adalimumab in Psoriasis, this one is the 22nd largest by enrollment, is one of 2 that started in 2008, is one of 26 in phase 3, and was the 5th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

The objective of this study was to evaluate the safety and efficacy profile of Humira (adalimumab) in patients who had a sub-optimal response to prior systemic therapy. This open-label study was conducted in a patient population of moderate to severe chronic plaque psoriasis patients, which is an approved patient population for adalimumab.

Read the detailed description

This 16-week multicenter, open-label study was designed to evaluate the efficacy and safety of a loading dose of 80 mg adalimumab, followed by 40 mg adalimumab every other week in the treatment of psoriasis in patients with a sub-optimal response to etanercept, methotrexate (MTX), or Narrow band Ultraviolet - B (NB-UVB).

Approximately 150 participants were planned for 3 sub-studies: 80 participants with sub-optimal response to etanercept, 40 participants with sub-optimal response to MTX, and 30 participants with sub-optimal response to NB-UVB. Actual enrollment was 82 participants with sub-optimal response to etanercept, 41 participants with sub-optimal response to MTX, and 29 participants with sub-optimal response to NB-UVB.

Screening was performed at least 96 hours and no more than 31 days before the Baseline visit (Week 0). A participant who was eligible for the study based on sub-optimal response to one treatment (MTX, NB-UVB, or etanercept) was required to discontinue that treatment within a specified time before first dose of adalimumab (see descriptions of sub-study groups). In addition, if the participant was also receiving another qualifying treatment, he/she was required to have discontinued the other treatment at least 30 days before the Baseline visit (Week 0).

Adalimumab was administered by subcutaneous (SC) injection. At the Baseline Visit (Week 0), all participants received an initial dose of 80 mg adalimumab SC. Every other week (odd-numbered weeks) from Week 1 to Week 15, participants received 40 mg adalimumab SC.

This was a single group assignment study, that is, all participants received the same treatment; however, data were summarized for 3 groups (sub-studies) that were defined by psoriasis treatments participants received before entering this study: methotrexate, etanercept, or narrow-band, ultraviolet-B.

Efficacy was evaluated using the Physician's Global Assessment (PGA) of disease severity, and patient-reported outcomes: Patient's Global Assessment (PTGA) of disease severity, the Psoriasis-related Pruritus Assessment, the Dermatology Life Quality Index (DLQI), a visual analog scale (VAS) for plaque psoriasis and psoriatic arthritis pain, the Medical Outcomes Study (MOS) Sleep Scale, and the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI: SHP).

Serious and nonserious adverse events were summarized by sub-study of participants (suboptimal response to MTX, suboptimal response to NB-UVB, and suboptimal response to etanercept).

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of chronic plaque psoriasis with disease duration of at least 6 months
  • Sub-optimal response to treatment with etanercept, methotrexate, or narrow-band UVB phototherapy

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with adalimumab
  • Multiple concomitant therapy restrictions and/or washouts (topicals, ultraviolet, other systemic psoriasis therapies)
  • Prior treatment with natalizumab
  • Concurrent active skin diseases/infections
  • Poorly controlled medical conditions
  • History of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease
  • History of certain cancers
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Open Label

    Biological: adalimumab

Interventions

  • Biologicaladalimumab

    Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16

    The PGA is a 6-point scale used to measure the severity of a patient's disease. Plaque elevation, scaling, and erythema are rated from 0= clear (no plaque elevation; no scaling; erythema=hyperpigmentation, pigmented macules, diffuse faint pink or red coloration) to 5=very severe (plaque elevation=very marked; scaling=very coarse; erythema=very severe \[extreme red coloration, dusky to deep red coloration\]).

    Time frame: Week 16

Secondary outcomes

  1. Number of Participants Achieving a PGA of Clear (0) at Week 16

    Time frame: Week 16

  2. Number of Participants Achieving at Least 1 Grade of Improvement in PGA at Week 16 Compared to Screening

    Time frame: From Screening to Week 16

  3. Number of Participants Achieving 0 or 1 on Patient's Global Assessment at Weeks 2, 4, and 8

    The Patient's Global Assessment of Psoriasis-Severity is a rating of how well their disease is controlled. 0=complete disease control; 1=good disease control; 2=limited disease control; 3=uncontrolled disease.

    Time frame: Weeks 2, 4, and 8

  4. Dermatology Life Quality Index (DLQI) Total Score

    The DLQI has 10 items and 6 subscales: symptoms and feelings (Q 1 and 2), daily activities (Q 3 and 4), leisure (Q 5 and 6), work and school (Q 7), personal relationships (Q 8 and 9), and treatment (Q 10). Participants rate how much their skin problem affected their life in previous week. Responses are 0 (not at all) to 3=very much. DLQI=total of scores for all items; max=30; min=0.

    Time frame: From Screening to Week 4 and Week 16

  5. Number of Participants Achieving DLQI Total Score of 0 at Week 4 and Week 16

    DLQI total score of 0 indicates psoriasis had no effect at all on participant's life.

    Time frame: Week 4 and Week 16

  6. Psoriasis-related Pruritus Assessment

    The Psoriasis-related Pruritus Assessment is a scale for evaluating pruritus-related to psoriasis over the previous week; values range from 0 (no itching) to 10 (severe itching). A decrease in score indicates an improvement in pruritus.

    Time frame: From Screening to Week 16

  7. Visual Analog Scale (VAS) for Pain Involving Psoriatic Plaques and/or Psoriatic Arthritis

    The participant rates his/her pain during the previous week on a 100 mm VAS, from 0=no pain to 100=pain as bad as it could be. A decrease in score indicates improvement.

    Time frame: From Screening to Week 16

  8. Percent Work Time Missed Due to Psoriasis

    Work and activity impairment due to psoriasis were evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), a 6-item questionnaire that measures effect of psoriasis on number of hours worked and the number of hours missed from work. It also measures the effect on productivity and regular activities: 0=no effect on work/daily activities; 10=psoriasis prevented me from working/doing daily activities. Decreases in values on each part indicate improvement. At Screening, percent time missed in the previous week ranged from 0% to 40%.

    Time frame: From Screening to Week 16

  9. Percent Overall Work Impairment Due to Psoriasis

    Percent overall work impairment was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) (described above). At Screening, overall impairment ranged from 0% to 94%. A decrease in percent overall work impairment indicates improvement.

    Time frame: From Screening to Week 16

  10. Percent Impairment While Working Due to Psoriasis

    Percent impairment while working was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), described above. At Screening, impairment while working ranged from 0% to 90%. A decrease in percent impairment indicates improvement.

    Time frame: From Screening to Week 16

  11. Percent Activity Impairment Due to Psoriasis

    Percent impairment in regular activities was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), described above. At Screening, activity impairment due to psoriasis ranged from 0% to 90%.

    Time frame: From Screening to Week 16

  12. Sleep Problems Index II

    Sleep Problems Index of the Sleep Scale from the Medical Outcomes Study reflects sleep disturbance, perceived sleep adequacy, daytime somnolence, and awakening short of breath or with headache. Participant rates each item from "none of the time" to "all of the time" for the previous 4 weeks. Scores are transformed to 0 to 100 scale; lower scores indicate less impairment. Decrease in score indicates improvement.

    Time frame: From Screening to Week 16

07

Results

Posted May 28, 2010

Participant flow

Patients who were previously treated with etanercept, methotrexate (MTX), or narrow-band ultraviolet-B (NB-UVB) and had a sub-optimal response were recruited for participation in the study.

Participant flow — Overall Study
MilestoneSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Started412982
Completed392473
Not completed259
Withdrew: Adverse event010
Withdrew: Withdrawal by subject001
Withdrew: Lost to follow-up111
Withdrew: Lack of efficacy124
Withdrew: Did not meet exclusion criteria002
Withdrew: Serious adverse event010
Withdrew: Noncompliant with drug administration001

Outcome measures

PrimaryNumber of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16

The PGA is a 6-point scale used to measure the severity of a patient's disease. Plaque elevation, scaling, and erythema are rated from 0= clear (no plaque elevation; no scaling; erythema=hyperpigmentation, pigmented macules, diffuse faint pink or red coloration) to 5=very severe (plaque elevation=very marked; scaling=very coarse; erythema=very severe \[extreme red coloration, dusky to deep red coloration\]).

Time frame:
Week 16
Reported as:
Number · Participants
Number of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16
ParticipantsSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Number of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16251440
SecondaryNumber of Participants Achieving a PGA of Clear (0) at Week 16
Time frame:
Week 16
Reported as:
Number · Participants
Number of Participants Achieving a PGA of Clear (0) at Week 16
ParticipantsSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Number of Participants Achieving a PGA of Clear (0) at Week 1615610
SecondaryNumber of Participants Achieving at Least 1 Grade of Improvement in PGA at Week 16 Compared to Screening
Time frame:
From Screening to Week 16
Reported as:
Number · Participants
Number of Participants Achieving at Least 1 Grade of Improvement in PGA at Week 16 Compared to Screening
ParticipantsSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Number of Participants Achieving at Least 1 Grade of Improvement in PGA at Week 16 Compared to Screening322359
SecondaryNumber of Participants Achieving 0 or 1 on Patient's Global Assessment at Weeks 2, 4, and 8

The Patient's Global Assessment of Psoriasis-Severity is a rating of how well their disease is controlled. 0=complete disease control; 1=good disease control; 2=limited disease control; 3=uncontrolled disease.

Time frame:
Weeks 2, 4, and 8
Reported as:
Number · Participants
Number of Participants Achieving 0 or 1 on Patient's Global Assessment at Weeks 2, 4, and 8
ParticipantsSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Week 2509
Week 413720
Week 8221329
SecondaryDermatology Life Quality Index (DLQI) Total Score

The DLQI has 10 items and 6 subscales: symptoms and feelings (Q 1 and 2), daily activities (Q 3 and 4), leisure (Q 5 and 6), work and school (Q 7), personal relationships (Q 8 and 9), and treatment (Q 10). Participants rate how much their skin problem affected their life in previous week. Responses are 0 (not at all) to 3=very much. DLQI=total of scores for all items; max=30; min=0.

Time frame:
From Screening to Week 4 and Week 16
Reported as:
Mean · Change in scores on a scale
Dermatology Life Quality Index (DLQI) Total Score
Change in scores on a scaleSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Week 4-4.8 ± 5.89-5.2 ± 5.45-3.3 ± 4.93
Week 16-7.0 ± 7.45-6.5 ± 6.44-3.8 ± 5.66
SecondaryNumber of Participants Achieving DLQI Total Score of 0 at Week 4 and Week 16

DLQI total score of 0 indicates psoriasis had no effect at all on participant's life.

Time frame:
Week 4 and Week 16
Reported as:
Number · Participants
Number of Participants Achieving DLQI Total Score of 0 at Week 4 and Week 16
ParticipantsSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Week 4622
Week 1612617
SecondaryPsoriasis-related Pruritus Assessment

The Psoriasis-related Pruritus Assessment is a scale for evaluating pruritus-related to psoriasis over the previous week; values range from 0 (no itching) to 10 (severe itching). A decrease in score indicates an improvement in pruritus.

Time frame:
From Screening to Week 16
Reported as:
Mean · Change in scores on a scale
Psoriasis-related Pruritus Assessment
Change in scores on a scaleSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Psoriasis-related Pruritus Assessment-2.9 ± 3.90-3.0 ± 2.96-1.7 ± 3.24
SecondaryVisual Analog Scale (VAS) for Pain Involving Psoriatic Plaques and/or Psoriatic Arthritis

The participant rates his/her pain during the previous week on a 100 mm VAS, from 0=no pain to 100=pain as bad as it could be. A decrease in score indicates improvement.

Time frame:
From Screening to Week 16
Reported as:
Mean · Change in scores on a scale
Visual Analog Scale (VAS) for Pain Involving Psoriatic Plaques and/or Psoriatic Arthritis
Change in scores on a scaleSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Visual Analog Scale (VAS) for Pain Involving Psoriatic Plaques and/or Psoriatic Arthritis-14.7 ± 24.41-21.4 ± 30.01-12.7 ± 29.90
SecondaryPercent Work Time Missed Due to Psoriasis

Work and activity impairment due to psoriasis were evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), a 6-item questionnaire that measures effect of psoriasis on number of hours worked and the number of hours missed from work. It also measures the effect on productivity and regular activities: 0=no effect on work/daily activities; 10=psoriasis prevented me from working/doing daily activities. Decreases in values on each part indicate improvement. At Screening, percent time missed in the previous week ranged from 0% to 40%.

Time frame:
From Screening to Week 16
Reported as:
Mean · Change in percent time missed
Percent Work Time Missed Due to Psoriasis
Change in percent time missedSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Percent Work Time Missed Due to Psoriasis0.7 ± 3.431.3 ± 4.75-0.1 ± 1.85
SecondaryPercent Overall Work Impairment Due to Psoriasis

Percent overall work impairment was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) (described above). At Screening, overall impairment ranged from 0% to 94%. A decrease in percent overall work impairment indicates improvement.

Time frame:
From Screening to Week 16
Reported as:
Mean · Change in % overall work impairment
Percent Overall Work Impairment Due to Psoriasis
Change in % overall work impairmentSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Percent Overall Work Impairment Due to Psoriasis-4.0 ± 28.06-6.4 ± 19.75-2.8 ± 16.92
SecondaryPercent Impairment While Working Due to Psoriasis

Percent impairment while working was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), described above. At Screening, impairment while working ranged from 0% to 90%. A decrease in percent impairment indicates improvement.

Time frame:
From Screening to Week 16
Reported as:
Mean · Change in % impairment while working
Percent Impairment While Working Due to Psoriasis
Change in % impairment while workingSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Percent Impairment While Working Due to Psoriasis-5.5 ± 30.31-8.0 ± 19.35-1.5 ± 18.46
SecondaryPercent Activity Impairment Due to Psoriasis

Percent impairment in regular activities was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), described above. At Screening, activity impairment due to psoriasis ranged from 0% to 90%.

Time frame:
From Screening to Week 16
Reported as:
Mean · Change in percent activity impairment
Percent Activity Impairment Due to Psoriasis
Change in percent activity impairmentSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Percent Activity Impairment Due to Psoriasis-13.3 ± 33.08-12.2 ± 25.62-4.7 ± 23.03
SecondarySleep Problems Index II

Sleep Problems Index of the Sleep Scale from the Medical Outcomes Study reflects sleep disturbance, perceived sleep adequacy, daytime somnolence, and awakening short of breath or with headache. Participant rates each item from "none of the time" to "all of the time" for the previous 4 weeks. Scores are transformed to 0 to 100 scale; lower scores indicate less impairment. Decrease in score indicates improvement.

Time frame:
From Screening to Week 16
Reported as:
Mean · Change in scores on a scale
Sleep Problems Index II
Change in scores on a scaleSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Sleep Problems Index II-9.7 ± 18.01-7.7 ± 15.82-2.0 ± 14.57

Adverse events

Collected over 26 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sub-optimal Response to MTX—0/41 (0%)19/41 (46.3%)
Sub-optimal Response to Narrow-band Ultraviolet-B—1/29 (3.4%)12/29 (41.4%)
Sub-optimal Response to Etanercept—4/82 (4.9%)20/82 (24.4%)
Most frequent serious events
Most frequent serious events
EventSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
CellulitisInfections and infestations0/411/290/82
Coronary artery diseaseCardiac disorders0/410/291/82
Diverticulitis Meckel'sCongenital, familial and genetic disorders0/410/291/82
Diverticular perforationGastrointestinal disorders0/410/291/82
Food poisoningGastrointestinal disorders0/410/291/82
PeritonitisGastrointestinal disorders0/410/291/82
Helicobacter pylori identification test positiveInvestigations0/410/291/82
ObesityMetabolism and nutrition disorders0/410/291/82
Most frequent other events
Showing 10 of 33
Most frequent other events
EventSub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to Etanercept
Upper respiratory tract infectionInfections and infestations5/411/295/82
Injection site erythemaGeneral disorders3/411/291/82
NasopharyngitisInfections and infestations3/410/293/82
FatigueGeneral disorders2/412/292/82
PharyngitisInfections and infestations0/412/290/82
GlaucomaEye disorders2/410/290/82
Injection site reactionGeneral disorders2/410/290/82
BronchitisInfections and infestations2/410/290/82
ContusionInjury, poisoning and procedural complications2/410/291/82
SunburnInjury, poisoning and procedural complications2/410/290/82

Baseline characteristics

Age Continuous
Age Continuous(years)Sub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to EtanerceptTotal
Mean47.4 ± 13.1145.7 ± 14.6048.3 ± 13.7047.6 ± 13.67
Sex: Female, Male
Sex: Female, Male(Participants)Sub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to EtanerceptTotal
Female13133561
Male28164791
Region of Enrollment
Region of Enrollment(participants)Sub-optimal Response to MTXSub-optimal Response to Narrow-band Ultraviolet-BSub-optimal Response to EtanerceptTotal
United States261070106
Canada15191246
08

Study locations

25 sites
  • Total Skin and Beauty Dermatology Centers
    Birmingham, Alabama 35205, United States
  • Dermatology Research of Arkansas
    Little Rock, Arkansas 72205, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • Florida Academic Dermatology Centers
    Miami, Florida 33136, United States
  • Peachtree Dermatology Associates
    Atlanta, Georgia 30327, United States
  • Dawes Fretzin Clinical Research Group
    Indianapolis, Indiana 46256, United States
  • ORA Clinical Research and Development
    Andover, Massachusetts 01810, United States
  • Montifiore Medical Center
    Bronx, New York 10467, United States
  • New York University School of Medicine
    New York, New York 10016, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Paddington Testing Co.
    Philadelphia, Pennsylvania 19103, United States
  • Clinical Partners
    Johnston, Rhode Island 02919, United States
  • Radiant Research
    Greer, South Carolina 29651, United States
  • Dermatology Treatment & Research Center, PA Research
    Dallas, Texas 75230, United States
  • Baylor Research Institute
    Dallas, Texas 75246, United States
  • Center for Clinical Studies
    Houston, Texas 77058, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23507, United States
  • Dermatology Associates
    Seattle, Washington 98101, United States
  • Kirk Barber Research
    Calgary, Alberta T2S 3B3, Canada
  • Stratica Medical
    Edmonton, Alberta T5K 1X3, Canada
  • Eastern Canada Cutaneous Research Associates
    Halifax, Nova Scotia B3H 1Z4, Canada
  • Dermatrials Research
    Hamilton, Ontario L8N 1V6, Canada
  • K.Papp Clinical Research Inc
    Waterloo, Ontario N2J 1C4, Canada
  • Siena Medical Research
    Montreal, Quebec, Canada
  • Centre de Rescherche Dermatologique Du Quebec Metropolitain
    Quebec City, Quebec G1V 4X7, Canada
09

References and documents

Publications

  • Strober BE, Poulin Y, Kerdel FA, Langley RG, Gu Y, Gupta SR, Okun MM, Papp KA. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011 Apr;64(4):671-81. doi: 10.1016/j.jaad.2010.03.009. PubMed 21414495 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2007
First posted
Dec 4, 2007
Start
Jan 2008
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
May 28, 2010
Last update
Apr 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00566722
Lead sponsor
Abbott
First posted
Dec 4, 2007
Start date
Jan 2008
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
May 28, 2010
Last update
Apr 12, 2011

Study contacts

Martin M Okun, M.D., Ph.D.
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion